• home
  • articles
  • authors
  • Reviewers
  • About the Journal
  • About the Journal
  • About the Journal
  • About the Journal
  • About the Journal
  • e-Submission

Indexed/Covered by

Evaluation of a fixed dose combination of benazepril and pimobendan in dogs with congestive heart failure; a randomized non-inferiority clinical trial
Jonathan N. King1,*, Atsushi.Hirakawa2, Junko Sonobe3, Hiroshi Otaki3, Nobuhiro Sakakibara3, Wolfgang Seewald1, Sophie Forster4
1Elanco Animal Health, Basel, CH-4002, Switzerland
2Pet Clinic Hallelujah, Nakahara, Kasuya-cho, Kasuya-gun, Fukuoka, 811-2304, Japan
3Elanco Animal Health Japan K.K., Tokyo, 107-0052, Japan
4Elanco Animal Health, Basingstoke, RG24 9NL, UK
Correspondence to: Tel: +41-61-685-6831; E-mail: jonathan.king@elanco.com
Received: September 1, 2016; Revised: March 1, 2017; Accepted: March 26, 2017; Published online: July 10, 2017.
Abstract
A new fixed dose combination tablet of benazepril and pimobendan (Fortekor Plus) was tested in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) in a prospective, multi-center, parallel-group, three-arm, masked, randomized, non-inferiority clinical trial in 67 dogs in Japan. The test group received Fortekor Plus twice daily (n=34). Two control groups received the registered formulations of benazepril (Fortekor) and pimobendan (Vetmedin) with administration of pimobendan twice daily and benazepril twice (Control I, n=14) or once (Control II, n=19) daily. Diuretics were used in 22 dogs (32.8%). The Global Clinical Score, assessed by veterinarians, decreased significantly from baseline in all groups. There were no significant differences between groups, and non-inferiority of Fortekor Plus was demonstrated compared to the Control I, Control II and combined Control I+II groups. There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events. The frequency of emesis was significantly (P=0.0042) lower in the Fortekor Plus (8.8%) compared to the Control I+II (39.4%) group. In conclusion, Fortekor Plus had non-inferior efficacy and was associated with significantly less emesis compared to administration of Fortekor and Vetmedin in dogs with CHF caused by MMVD.
Keywords: benazepril, congestive heart failure, dog, pimobendan


© 2017 The Korean Society of Veterinary Science.